ES2482866B1 - Método de diagnóstico y/o pronóstico de enfermedades neurodegenerativas. - Google Patents

Método de diagnóstico y/o pronóstico de enfermedades neurodegenerativas. Download PDF

Info

Publication number
ES2482866B1
ES2482866B1 ES201231807A ES201231807A ES2482866B1 ES 2482866 B1 ES2482866 B1 ES 2482866B1 ES 201231807 A ES201231807 A ES 201231807A ES 201231807 A ES201231807 A ES 201231807A ES 2482866 B1 ES2482866 B1 ES 2482866B1
Authority
ES
Spain
Prior art keywords
seq
mitochondrial dna
adn
mitocondrial
csf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201231807A
Other languages
English (en)
Spanish (es)
Other versions
ES2482866A1 (es
Inventor
Ramon Trullas Oliva
Joana FIGUEIRÓ SILVA
Petar MIHAYLOVICH PODLESNIY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro De Investigacion Biomedica En Red De Enferm
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas CIBERNED
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas CIBERNED filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to ES201231807A priority Critical patent/ES2482866B1/es
Priority to JP2015543486A priority patent/JP2016502406A/ja
Priority to PCT/ES2013/070713 priority patent/WO2014080054A1/es
Priority to EP13856389.5A priority patent/EP2924124A4/en
Priority to US14/443,607 priority patent/US20150361495A1/en
Publication of ES2482866A1 publication Critical patent/ES2482866A1/es
Application granted granted Critical
Publication of ES2482866B1 publication Critical patent/ES2482866B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES201231807A 2012-11-22 2012-11-22 Método de diagnóstico y/o pronóstico de enfermedades neurodegenerativas. Expired - Fee Related ES2482866B1 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES201231807A ES2482866B1 (es) 2012-11-22 2012-11-22 Método de diagnóstico y/o pronóstico de enfermedades neurodegenerativas.
JP2015543486A JP2016502406A (ja) 2012-11-22 2013-10-17 神経変性疾患の診断及び／又は予知の方法
PCT/ES2013/070713 WO2014080054A1 (es) 2012-11-22 2013-10-17 Método de diagnóstico y/o pronóstico de enfermedades neurodegenerativas
EP13856389.5A EP2924124A4 (en) 2012-11-22 2013-10-17 METHOD FOR DIAGNOSIS AND / OR FORECASTING NEURODEEGENERATIVE DISEASES
US14/443,607 US20150361495A1 (en) 2012-11-22 2013-10-17 Method for the diagnosis and/or prognosis of neurodegenerative diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201231807A ES2482866B1 (es) 2012-11-22 2012-11-22 Método de diagnóstico y/o pronóstico de enfermedades neurodegenerativas.

Publications (2)

Publication Number Publication Date
ES2482866A1 ES2482866A1 (es) 2014-08-04
ES2482866B1 true ES2482866B1 (es) 2015-05-12

Family

ID=50775580

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201231807A Expired - Fee Related ES2482866B1 (es) 2012-11-22 2012-11-22 Método de diagnóstico y/o pronóstico de enfermedades neurodegenerativas.

Country Status (5)

Country Link
US (1) US20150361495A1 (enExample)
EP (1) EP2924124A4 (enExample)
JP (1) JP2016502406A (enExample)
ES (1) ES2482866B1 (enExample)
WO (1) WO2014080054A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3181701A1 (en) * 2015-12-17 2017-06-21 Consejo Superior De Investigaciones Cientificas Method for the sub-classification of patients suffering from parkinson disease
US20190119747A1 (en) * 2016-03-28 2019-04-25 Osaka University Stress biomarker
WO2017170571A1 (ja) * 2016-03-28 2017-10-05 国立大学法人大阪大学 眼科疾患のバイオマーカー
FR3144164A1 (fr) * 2022-12-23 2024-06-28 Neolys Diagnostics Détermination du statut d’un individu vis-à-vis de la maladie d’Alzheimer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494794A (en) * 1992-10-20 1996-02-27 Emory University Detection of mitochondrial DNA mutations associated with Alzheimer's disease and Parkinson's disease
EP0812922A3 (en) * 1996-05-16 2002-08-21 Affymetrix, Inc. (a California Corporation) Polymorphisms in human mitochondrial nucleic acid
US6441149B1 (en) * 1998-06-15 2002-08-27 Mitokor Diagnostic method based on quantification of extramitochondrial DNA
US6218117B1 (en) * 1998-06-15 2001-04-17 Mitokor Compositions and methods for identifying agents that quantitatively alter detectable extramitochondrial DNA:mitochondrial DNA ratios
WO2000063441A2 (en) * 1999-04-20 2000-10-26 Mitokor Single nucleotide polymorphisms in mitochondrial genes that segregate with alzheimer's disease
WO2002097124A1 (en) * 2001-05-29 2002-12-05 The University Of British Columbia Pharmacological applications of mitochondrial dna assays
US20040009518A1 (en) * 2002-05-14 2004-01-15 The Chinese University Of Hong Kong Methods for evaluating a disease condition by nucleic acid detection and fractionation
WO2007011322A2 (en) 2004-03-29 2007-01-25 The Regents Of The University Of California Methods and compositions for diagnosis of alzheimer's disease and other neurodegenerative disorders
WO2006111029A1 (en) * 2005-04-18 2006-10-26 Genesis Genomics Inc. Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
EP2557421A3 (en) * 2007-03-23 2013-06-05 King's College London Altered mitochondrial activity in diseases resulting from oxidative stress
US9050275B2 (en) * 2009-08-03 2015-06-09 Theta Biomedical Consulting & Development Co., Inc. Methods of screening for and treating autism spectrum disorders and compositions for same
WO2011066476A1 (en) * 2009-11-25 2011-06-03 Quantalife, Inc. Methods and compositions for detecting genetic material
JP5831919B2 (ja) * 2011-02-21 2015-12-09 国立大学法人北海道大学 神経変性疾患の検査方法

Also Published As

Publication number Publication date
ES2482866A1 (es) 2014-08-04
EP2924124A1 (en) 2015-09-30
US20150361495A1 (en) 2015-12-17
JP2016502406A (ja) 2016-01-28
EP2924124A4 (en) 2016-08-31
WO2014080054A1 (es) 2014-05-30

Similar Documents

Publication Publication Date Title
Podlesniy et al. Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease
US20190002982A1 (en) Systems For Biomarker Detection
Marques et al. Epigenetic regulation of BACE1 in Alzheimer’s disease patients and in transgenic mice
US10041959B2 (en) Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
Lue et al. TREM 2 Protein Expression Changes Correlate with A lzheimer's Disease Neurodegenerative Pathologies in Post‐Mortem Temporal Cortices
Winton et al. A90V TDP‐43 variant results in the aberrant localization of TDP‐43 in vitro
De Castro et al. Lamin b1 polymorphism influences morphology of the nuclear envelope, cell cycle progression, and risk of neural tube defects in mice
Kudo et al. Integrative gene–tissue microarray-based approach for identification of human disease biomarkers: application to amyotrophic lateral sclerosis
Arai Significance and limitation of the pathological classification of TDP‐43 proteinopathy
ES2482866B1 (es) Método de diagnóstico y/o pronóstico de enfermedades neurodegenerativas.
Wong et al. EIF2AK3 variants in Dutch patients with Alzheimer's disease
Bagyinszky et al. Studies of genetic and proteomic risk factors of amyotrophic lateral sclerosis inspire biomarker development and gene therapy
Carecchio et al. Cerebrospinal fluid biomarkers in progranulin mutations carriers
Nakata et al. Plasma microRNA miR-26b as a potential diagnostic biomarker of degenerative myelopathy in Pembroke welsh corgis
CN112980941A (zh) 一种诊断受试者是否患阿尔茨海默病的试剂盒及其用途
US11041205B2 (en) Molecular targets for ALS and related disorders
US11492669B2 (en) MicroRNA-455-3p as a peripheral biomarker for Alzheimer's disease
Washington et al. Peripheral markers of TBI and blood− brain barrier disruption
Wang et al. Spatiotemporal transcriptomic profiling reveals metabolic dysfunction prior to overt tauopathy in the PS19 mouse model
Rogers Cis-Regulatory Elements: Relevance for Alzheimer's Disease
Seto-Salvia et al. Elevated 4R-tau in Astrocytes From Asymptomatic Carriers of the MAPT 10+ 16 Mutation
Dourte et al. An Early Olfactory Transcriptomic Signature of Tauopathy: Gbp2b Emerges as a Candidate Biomarker of Tau-Driven Neuroinflammation
Hua et al. Microglial P2X4 receptors promote ApoE degradation and cognitive deficits in Alzheimer disease
WO2017103266A1 (en) Method for the sub-classification of patients suffering from parkinson disease
WO2025125705A1 (es) Biomarcadores nucleares de la enfermedad de alzheimer, sus usos y métodos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2482866

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150512

PC2A Transfer of patent

Effective date: 20180525

Owner name: CENTRO DE INVESTIGACION BIOMEDICA EN RED DE ENFERM

Effective date: 20180525

FD2A Announcement of lapse in spain

Effective date: 20240326